Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC... | June 3, 2023

Related Keywords

Foster City ,California ,United States ,Dimitry Sa Nuyten ,Melissal Johnson , ,Astrazeneca ,Exchange Commission ,Arcus Biosciences Inc ,Gilead Sciences ,Sarah Cannon Research Institute ,Lung Cancer Research ,Gilead Sciences Inc ,Nasdaq ,Arcus Biosciences ,Rapid Abstract Updates ,Lead Investigator ,Free Survival ,Response Rate ,Chief Medical Officer ,Bill Grossman ,Senior Vice President ,Therapeutic Area Head ,Response Evaluation Criteria ,Solid Tumors ,Arcus Bioscience ,Private Securities Litigation Reform Act ,Quarterly Report ,Nc Stock Exchange ,News ,Information ,Press Release ,Linically ,Meaningful ,Reduction ,N ,Risk ,F ,Progression ,Dr ,Death ,Gas ,Bserved ,The ,Study ,Arms ,Ompared ,O ,Zimberelimab ,Monotherapy ,N Rcus Us03969f1093 ,